Skip to main content

Amiodarone-Induced Thyrotoxicosis in a Patient with Multinodular Goiter

  • Chapter
  • First Online:
Thyroid and Parathyroid Diseases
  • 1179 Accesses

Abstract

An old male who presented with atypical symptoms was diagnosed with thyrotoxicosis. He had multinodular goiter and was taking amiodarone (probably intermittently for a long time) for atrioventricular arrhythmias. The findings were interpreted in favor of amiodarone thyroiditis, but it was difficult to distinguish the type of amiodarone-induced thyrotoxicosis (AIT) because findings of both type 1 and 2 AIT were observed. Combined antithyroid drug (methimazole 20 mg/day) and corticosteroid (prednisolone 40 mg/day) were administered to treat both types of AIT. Normal thyroid hormone levels were found in the second week of treatment. Hepatotoxicity and decreasing platelet count developed as side effects of methimazole; therefore, the drug was stopped. Prednisolone was continued at the same dosage for 4 weeks and tapered to 6–10 mg every 4 weeks. Meanwhile, liver enzyme levels and platelet count returned to acceptable levels, but there was a risk of exacerbation. The patient was operated during the fourth month of follow-up when his cardiac problems were stable.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Samuels MH, Franklyn JA. Hyperthyroidism in aging. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Source endotext [internet]. South Dartmouth, MA: MDText.com, Inc.; 2000. Available at http://www.ncbi.nlm.nih.gov/books/NBK278986/.

    Google Scholar 

  2. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343–421.

    Article  PubMed  Google Scholar 

  3. Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol. 1984;3:1059–71.

    Article  CAS  PubMed  Google Scholar 

  4. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298:1312–22.

    Article  CAS  PubMed  Google Scholar 

  5. Narayana SK, Woods DR, Boos CJ. Management of amiodarone-related thyroid problems. Ther Adv Endocrinol Metab. 2011;2:115–26. https://doi.org/10.1177/2042018811398516.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Jabrocka-Hybel A, Bednarczuk T, Bartalena L, Pach D, Ruchała M, Kamiński G, et al. Amiodarone and the thyroid. Endokrynol Pol. 2015;66:176–86. https://doi.org/10.5603/EP.2015.0025.

    Article  CAS  PubMed  Google Scholar 

  7. van Beeren HC, Bakker O, Wiersinga WM. Structure-function relationship of the inhibition of the 3,5,3′-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs. Endocrinology. 1996;137:2807–14.

    Article  PubMed  Google Scholar 

  8. Tomisti L, Rossi G, Bartalena L, Martino E, Bogazzi F. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol. 2014;171:363–8. https://doi.org/10.1530/EJE-14-0267.

    Article  CAS  PubMed  Google Scholar 

  9. Czarnywojtek A, Czepczynski R, Ruchala M, Wasko R, Zgorzalewicz-Stachowiak M, Szczepanek E, et al. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT). Neuro Endocrinol Lett. 2009;30:209–14.

    CAS  PubMed  Google Scholar 

  10. Pierret C, Tourtier JP, Pons Y, Merat S, Duverger V, Perrier E. Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation? J Laryngol Otol. 2012;126:701–5. https://doi.org/10.1017/S0022215112000722.

    Article  CAS  PubMed  Google Scholar 

  11. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. https://doi.org/10.1089/thy.2015.0020.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Salman, S. (2019). Amiodarone-Induced Thyrotoxicosis in a Patient with Multinodular Goiter. In: Özülker, T., Adaş, M., Günay, S. (eds) Thyroid and Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-78476-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-78476-2_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-78475-5

  • Online ISBN: 978-3-319-78476-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics